DRUG · Mapped RxNorm record
Alteplase
Normalized identity: alteplaseView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism
NCT03988842
Drugs and interventions used in this trial
4 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Unmapped registry intervention
Unfractionated heparin
Find medicine records ·
Find other trials using this name
DRUG · Unmapped registry intervention
Placebo
Find medicine records ·
Find other trials using this name
DRUG · Mapped RxNorm record
Apixaban
Normalized identity: apixabanView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedStandard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism
Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE4
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Pulmonary Embolismverified · MONDO: pulmonary embolism
Pulmonary Embolism Subacute Massiveunresolved
Right Ventricular Dysfunctionunresolved
Right Ventricular Failureunresolved
Interventions
Sponsors & collaborators
Victor Tapson, MDlead sponsor
Bristol-Myers Squibbcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03988842 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.